Teva Pharmaceuticals Industries Ltd (NYSE: TEVA) is the world's largest generic drug maker, with over 500 generic and biosimilar treatments in its broad portfolio. The medical sector giant also has a line of branded drugs driving growth.
Its specialty medicines address specific conditions, including respiratory diseases, oncology, and central nervous system (CNS) disorders. Its stock took a 17% tumble in the days following its fourth quarter of 2024 earnings release. Teva’s cautious full-year 2025 guidance fell short of consensus analyst estimates. With shares trading at just 6.8x forward earnings, value investors may view this as a dip buying opportunity.
